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Summary: Na^/Mg24" antiport and Na+-independent Mg24" efflux were investigated in erythrocytes of 41 patients
with cystic fibrosis and 26 controls. Na+-independent Mg2"1" efflux was unchanged in cystic fibrosis, but a signifi-
cantly increased activity of Na+/Mg2+ antiport was detected (control: 0.16 ± 0.02, cystic fibrosis: 0.39 ± 0.06,
Mg2+ efflux, mmol/30min X l cells, mean ± SEM, p < 0.01). An increased activity of Na+/Mg2+ antiport was
only found in patients with severe clinical Symptoms. There was no correlation of the increased Na+/Mg2+ antiport
to the dF508 genotype. In a patient with increased Na"*"/Mg2"1" antiport, the capacity of this transport System was
unchanged 14 weeks after double lung transplantation but reached control values after 53 weeks. The sweat of
cystic fibrosis patients with severe clinical Symptoms showed a significantly increased Mg2"1" concentration (control
(n = 12): 0.053 ± 0.08, cystic fibrosis (n = 9): 0.123 ± 0.016 mmol/1, mean ± SEM, p < 0.001).
Introduction
In patients with cystic fibrosis the cystic fibrosis trans-
membrane conductance regulator is mutated. A deletion
of phenylalanine at codon 508 is found in about 70% of
Caucasian cystic fibrosis patients; hundreds of different
mutations of the cystic fibrosis gene have been de-
scribed in the remaining 30% of patients (1). Besides
the defect in eAMP-dependent Chloride transport, other
defects have been observed1 in cystic fibrosis, such äs
increased Na+ äbsorption across airway epithelia, re-
duced mucin .secretion from salivary gländs and
increased sulphatation of glycoconjugates secreted by
airway epithelia (äs reviewed in 1. c. (2)). It has been
suggested that these defects are secondary to the reduced
Cl~ conductance, ör that they may represent additional
regulatory functions of cystic fibrosis transmembrane
conductance regulator. The latter not only functions äs a
Cl" channel but also seeins to iiifluence the activity of
other transport proteins by leading to a cystic fibrosis
transmembrane conductance regulator-associated pro-
tein kinase A activation, for example, of the outwardly
rectifying Chloride channel (3). In cystic fibrosis, re-
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duced Cl transport via both Cl channels contributes
to the disturbed Cl~~ secretion.
During the last few years Mg2+ efflux Systems of eryth-
rocytes have been characterised. Mg2+ efflux from
Mg2"Moaded erythrocytes proceeds via an electroneutral
Na+/Mg2+ antiport which transports two Na"1" for one
Mg24" and can be reversibly inhibited by amiloride (4).
This transport, therefore, represents an amiloride inhibit-
able Na"4" influx pathway. Amiloride is currently being
used äs a therapeutic agent in cystic fibrosis, inhibiting
Na"1" (and secondary H2O) uptake into the bronchial epi-
thelial cells, thereby leading to a decrease of mucus vis-
cosity (5). Additionally to Na^/Mg2"1" antiport, erythro-
cytes possess a Na^-independent Mg2+ efflux System.
This Mg24" efflux is accompanied by Cl"" efflux for
Charge compensation. Reduction of the Cl~ efflux by
high extracellular Cl~ or Cl"" channel blockers like 4,4f-
diisothiocyanatostilbene-2,2'-disulphonic acid also di-
minish Mg2"*" efflux across this System, an efFect which
can be overcome by the lipophilic cation tetraphenyl-
phosphonium (6). As Mg2* efflux is coupled either to
Cl"" or to Na"1" transport, investigations were performed
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to determine whether these Mg2+ transport Systems
might be changed in cystic fibrosis. In a preliminary
report it was shown that the Mg2+ content of erythro-
cytes was not changed in cystic fibrosis, but the Mg24"
efflux capacity of erythrocytes was increased in some
patients (7). Here it is reported that Na+/Mg2+ antiport
is significantly increased in cystic fibrosis patients with
severe clinical Symptoms, that it is accompanied by an
increased Mg2"1" concentration in sweat, and that it is not
coupled to the dF508 genotype of cystic fibrosis.
Materials and Methods
Patients
Cystic fibrosis patients (n = 41; 23 female, 18 male) and 26 age
matched controls (11 female, 15 male) not affected with cystic
fibrosis were included in the study. Age (in years), mean ± SD:
patients 19.4 ± 10.3, controls 21.4 ± 14.4. All patients had chronic
Pseudomonas aeroginosa infection of the lungs, suffered from pan-
creas insufficiency, and had not been treated with amiloride. The
patients were routinely genotyped. Patients were divided into three
groups based on the severity of their clinical Symptoms, accofding
to the Shwachman score without X-ray examination (8): mild
(CF1) > 55, medium (CF2) 55-41, severe (CF3) < 41 points.
Sweat fest
Sweat tests were performed on the forearm with pilocarpine ionto-
phoresis with a Webster sweat inducer System (Wescor, Logan,
Utah, USA). For measurement of the Mg2+ concentration in sweat
10 μΐ samples were diluted with l ml 100 g/l trichloroacetic acid/
l .75 g/l LaCla and Mg2"1" was measured by atomic absorption spec-
trophotometry (AAS, Philips SP9).
Mg2 + efflux
Heparinized blood was taken from controls and cystic fibrosis pa-
tients. Blood was centrifuged at 1000g for 10 min. The erythro-
cytes were taken for the measurement of Mg2"4" efflux, s already
described (4). Briefly, the cells were loaded with Mg2"1" by incubat-
ing a cell Suspension (volume fraction 0.1) for 30 min at 37 °C in
KC1 medium (in mmol/1: 140 KC1, 12 MgCl2, 50 sucrose, 5 glu-
cose, 30 Hepes/Tris, pH 7.4). With the addition of 6 μιηοί/Ι of the
cation ionophore A23187 (Boehringer Mannheim, Germany) dis-
solved in dimethyl sulphoxide. For removal of the ionophore, the
cells were incubated four times in KC1 medium plus 10 g/l bovine
serum albumin for 10 min at 37 °C. The KC1 medium was removed
by washing the cells twice with cold (4 °C) choline Chloride me-
dium (in mmol/1: 140 choline Chloride, 5 glucose, 30 Hepes/Tris,
pH 7.4).
Mg2"4" efflux was measured by reincubating a cell Suspension (vol-
ume fraction 0.1) at 37 °C in Mg2H"-free N Cl medium (Substitution
of KC1 in KC1 medium by 140 mmol/1 NaCl) or Mg2+-free choline
Chloride medium (Substitution of KC1 in KC1 medium by 140
mmol/1 choline Chloride). At the beginning of reincubation and af-
ter 30 min, 0.5 ml aliquots of the cell suspensions were centrifuged
for l min at 10000#. Aliquots (100 μΐ) of the supernatants were
diluted with l ml 100 g/l trichloroacetic acid/1.75 g/l LaCl3, and
Mg2* was measured by AAS. Mg2+ efflux was calculated from
the increase of Mg2+ in the reincubation media and was related to
cell volume. Cell volume was determined by measuring the haema-
tocrit and the haemoglobin content of a cell lysate. Na+-dependent
Mg2+ efflux (Na+/Mg2"*· antiport) was determined by subtracting
Mg2+ efflux in choline chloride medium (which represents Na+-
independent Mg2+ efflux at physiological extracellular Cl con-
centration) from Mg2"*" efflux in Na"*" medium.
Results
Table l shows that Na+-indepei\dent Mg2+ efflux, which
is accompanied by Cl~ efflux, is not changed in cystic
fibrosis. The mean Na+/Mg2H" antiport, however, is more
than doubled in cystic fibrosis patients. The elevated
mean is due to high values in some patients, whereas
other patients had normal antiport rates. By dividing the
patients into three groups according to the severity of
their disease, it was obvious that particularly patients
with severe cliriical Symptoms (CF3) showed an
increased Na^/Mg2"1" antiport capacity, whereas none of
the other patients (CF1 or CF2) showed ahy change in
transport capacity (tab. 2, fig. 1). In all patients with
increased Na~*7Mg2+ antiport, this transport was inhib-
ited by l mmol/1 amiloride (fig. 1), which also inhibited
Na^/Mg2"1" antiport in controls and cystic fibrosis pa-
tients with normal transport rates. Figure 2 shows the
Na+/Mg2+ antiport rates of patients with the homozy-
gous dF508 mutation, classified according to the
Shwachman score. The increased Na^/Mg2"1" antiport
could not be attributed to a specific m tation of the cys-
tic fibrosis gene s some patients with the homozygous
dF508 m tation showed a normal N +/Mg2+ antiport,
while in others it was increased. Also in the rem ining
Tab, l Na+/Mg2+ antiport and Na+-independent Mg2+ efflux
from Mg2"*"-loaded erythrocytes from eontrols and cystic fibrosis
patients. Mean ± SEM. Significant difference between control and
cystic fibrosis patients by Mann-Whitney test; **, p < 0.01.
Na+-independent
Mg2+ effluxantiport
(Mg2+ efflux,
mmol/30 min. X l cells)
Control
Cystic fibrosis
26
41
0.16 ±0.02
0.39 ± 0.06**
0.12 ± 0.01
0.13 ± 0.01
Tab. 2 Na^/Mg2"1" antiport from Mg2+-loaded erythroeytes of
controls and cystic fibrosis patients. The patients were grouped
according to the severity of their disease, CF1 (mild), CF2 (me-
dium), CF3 (severe), for details see Methods. Mean ± SEM. Sig-
nificant difference between control and cystic fibrosis patient
groups by Mann-Whitney test; ***, p < 0.001.
antiport
(Mg2+ efflux,
mmol/30 min X l celis)
Control
CF1
CF2
CF3
26
9
10
22
0,16 ±0.02
0.19±0ϊ02
0.13 ± 0.02
0.63 ± 0.10***
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Fig. l Na+TMg2"1" antiport in Mg2~Moaded erythrocytes from
controls and patients with cystic fibrosis. Incubation without (-)
or with (+) l mmol/1 amiloride (Sigma, München, Germany). Na"1"/
Mg2"1" antiport is determined äs Mg24" efflux in NaCl medium mi-
nus efflux in choline Chloride medium. CF1, CF2 and CF3 are
cystic fibrosis patients subdivided into groups according to the se-
verity of their clinical Symptoms (for details see Methode).
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Fig. 2 Na+/Mg2+ antiport in Mg2+-loaded erythrocytes from cys-
tic fibrosis patients with the homozygous dF508 mutation subdi-
vided into groups according to the severity of their clinical Symp-
toms.
patients (dF508 heterozygous with additional mutations,
or homozygous for mutations of the eystic fibrosis gene
öther thän dF508) no correlatiqn between genotype and
Na+/Mg2+ antiport could be detected.
One patient with increased Na+/Mg2+.ajitiport (Mg2+
efflux: 0.58 minol/30 min X l cells) underwent double
lung transplantation. Fourteen weeks after transplanta-
tion, Mg2+ efflux was älmöst the same (0.54 mmol/30
min X l cells), althoügh the clinical Symptoms had
greatly improved. However, 53 weeks after lung trans-
plantation Na+/Mg?+ antiport was normalised (Mg2+ ef-
flux, 0.22 iximol/3.0 min X l cells).
Results for the Mg2* concentration in the sweat of cystic
fibrosis patients were similar to those obtained for Na+/
Mg2"1" antiport (tab. 3), i.e. only the patients with the
Jiighest severity score (CF3) showed significantly
increased sweat Mg2+ concentrations.
Discussion
Intracellular Mg2+ is needed for many physiological and
metabolic fimctions, i. e. activation of enzymes, charge
reduction of negatively loaded substances like DNA or
RNA and regulation of ion channels (9). To fulfil these
tasks, the intracellular concentration of free Mg2"1"
([Mg2+]i) has to be kept within narrow limits. Only 5%
of total intracellular Mg2+ is ionised, and the concentra-
tion ränge of [Mg2H~]i is about 0.2—1.0 mmol/1, depend-
ing on cell type. [Mg2"l"]i increases when Mg2"1" is re-
leased from intracellular ligands, i. e. after breakdown of
ATP or intracellular acidification. Thereafter, it is nor-
malised by activation of Mg2"1" efflux Systems, especially
electroneutral Na+/Mg2+ antiport. Na+/Mg2+ antiport
works only at increased intracellular free Mg2+ concen-
tration. Under these conditions it represents a Na"1" influx
and Mg24" efflux pathway which has been found in sev-
eral cell types (erythrocytes, thymocytes, cardiomyo-
cytes, hepatocytes, HL60 cells) of different species with
different transport capacities. TTiis transport system is
not identical with any of the other Na+ influx Systems
(e. g. Na"l"/H"f or Na^/Ca2"1" exchange) (review in 1. c.
(10)). As we report here, in human erythrocytes it is
specifically increased in a sub-population of cystic fi-
brosis patients with a severe clinical condition.
The increased Na+/Mg2H~ antiport in cystic fibrosis is
not coupled to the dF508 genotype or any other known
mutation of the cystic fibrosis gene, äs patients with ho-
mozygous dF508 mutations display normal äs well äs
increased antiport. It is likely that the increased Na+/
Mg24" antiport is caused by an äs yet unknown effect of
the disease that only develops in a subgroup of severely
affected patients. In accprdance with this result, the clin-
ical severity of cystic fibrosis was also not correlated
with the genotype (1). This also agrees with the findings
after lung transplantation. Transplantation of the lung
induced normalisation of Na^/Mg2"1" antiport of the
Tab. 3 Mg2"1" concentration in sweat of controls and cystic fibro-
sis patients, grouped according to table 2. Mean ± SEM. Signifi-
cant difference between control and cysric fibrosis patient groups
by Mann-Wliiiney test; ***, p < 0.001.
n [Mg2+] in sweat
(mmol/l)
Control
CF1
CF2
CF3
12
4
10
9
0.053 ± 0.008
0.060 ±0.015
0.070 ±0.010
0.123 ± 0.016***
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erythrocytes. Tlie lag period may be explained by the
turnover rate of the erythrocytes. In the transplanted pa-
tient all clinical problems remained unchanged except
respiratory distress. Therefore, the increased Na+/Mg2+
antiport must be caused by the affected lung. Another
possibility might be a long term effect of the immuno-
suppressive therapy on the increased transport. A higher
rate of oxygen radical production due to the lung infec-
tion in cystic fibrosis patients seems not to be the cause
of the increased Na+/Mg2+ antiport, äs oxygen radicals
induced a reduction and not an increase of Na^/Mg2*
antiport (11).
Increased transport rates of Na+/Mg2+ antiport should
lead to higher transcellular Mg2+ fluxes. The increased
Mg2+ content in the sweat of the CF3 group could be
explained by higher transcellular Mg?+ fluxes due to
increased Na~*~/Mg2+ antiport. Due to the small amount
of transported Mg2+, the increased Na4" uptake via Na+/
Mg2+ antiport would not significantly change the Na+
content of sweat. Paunier et al. (12) reported similar
values for the Mg24" content of sweat in controls, but
did not find a significant difference between controls
and cystic fibrosis children. However, they did not di-
vide their patients into subgroups according to the sever-
ity of diseäse and, therefore, might have overlooked
increased Mg24" concentrations by just comparing
means, or might have had a population of patients with
mild or modest clinical Symptoms.
If Na+/Mg2+ antiport is increased not only in erythro-
cytes but also in other cell types, then intracellular Mg24"
may be reduced in these other cell types, A high Mg2+
supply would then be beneficial to these cystic fibrosis
patients.
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